Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Neurology

Your Future: Monitoring, Safety, and Quality of Life

At a Glance

Living with a genetic neuropathy requires lifelong monitoring to preserve nerve function. While most types do not affect life expectancy, protecting nerves from toxic medications, excess Vitamin B6, and alcohol is crucial. Daily foot checks and regular neurology exams help maintain quality of life.

Living with a genetic neuropathy is a marathon, not a sprint. Because these conditions are usually progressive, meaning they change slowly over time, the goal of long-term care is to preserve your function, prevent complications, and maintain your quality of life. Understanding what to expect can help you feel more in control of your future [1][2].

Long-Term Outlook and Life Expectancy

The prognosis for genetic neuropathy varies significantly depending on the specific type:

  • CMT and HNPP: For the majority of people with CMT (like CMT1A) and HNPP, life expectancy is normal [1][3]. While the condition is progressive and may lead to increased difficulty with walking or using your hands, it is generally not fatal [4].
  • hATTR (Amyloidosis): This condition is different because it is a systemic disease. Without treatment, hATTR can be fatal because the toxic protein clumps (amyloid) can damage the heart and other vital organs [5][4]. However, with modern gene-silencing therapies, the outlook has improved significantly for those diagnosed early [6].

Protecting Your Nerves: What to Avoid

When you have a genetic neuropathy, your nerves are already under stress. Certain substances can be “neurotoxic,” meaning they can cause additional damage and make your symptoms worse [7].

High-Risk Medications

Some medications are known to be dangerous for people with CMT. The most critical is Vincristine, a chemotherapy drug that can cause a rapid and severe drop in nerve function in CMT patients [8][9]. Other drugs, like certain antibiotics or heart medications (e.g., amiodarone), may also carry risks. Always share your diagnosis with any specialist prescribing new medication [7][2].

The “Vitamin B6” Warning

While Vitamin B6 is essential for nerve health, taking too much of it (pyridoxine toxicity) can actually damage nerves [7]. Many people with neuropathy take supplements hoping to help, but if you have a genetic condition, high doses of B6 can be counterproductive. Consult your doctor before taking high-dose B-complex vitamins.

Alcohol

Alcohol is inherently toxic to peripheral nerves. While a single glass of wine occasionally may be fine for some, excessive or regular alcohol consumption can accelerate nerve damage in people who already have a genetic vulnerability [7]. It is best to minimize alcohol intake to protect your remaining nerve function.

A Lifetime Surveillance Schedule

Proactive monitoring can catch problems before they become severe. A typical “maintenance” schedule might include:

Frequency Action Why?
Daily Foot Check Look for sores or blisters you might not feel [10].
Annually Neurology Exam Track strength, balance, and update your therapy plan [2].
Annually Physical Therapy Review Ensure your exercises are still effective and not too fatiguing [11].
As Needed Orthotics Check Replace worn-out AFOs or adjust for changes in foot shape [12].
Variable Cardiac/Sleep Check Required for specific types (like hATTR or CMT1B) to monitor heart or breathing [13][5].

The Emotional Landscape

Living with a chronic, progressive condition takes an emotional toll. It is common to feel frustration, grief over lost abilities, or anxiety about the future [14][15]. This is not “all in your head”—it is a natural response to a complex health journey. Seeking support through counseling or patient advocacy groups can provide a vital space to process these feelings and connect with others who understand the unique challenges of genetic neuropathy [16][2].

Common questions in this guide

Does genetic peripheral neuropathy affect life expectancy?
For most forms of genetic neuropathy, such as CMT and HNPP, life expectancy is completely normal. However, systemic forms like hATTR can be life-threatening without treatment, though modern gene therapies have significantly improved the long-term outlook.
Are there specific medications I should avoid with a genetic neuropathy?
Yes, certain drugs can be toxic to already vulnerable nerves and rapidly worsen symptoms. The chemotherapy drug Vincristine is especially dangerous. Always make sure any doctor prescribing new medications knows about your genetic neuropathy diagnosis.
Is it safe to take Vitamin B6 supplements for my nerve health?
While normal amounts of Vitamin B6 are essential for health, taking high-dose supplements can actually cause further nerve damage. You should always consult your neurologist before taking any B-complex vitamins or supplements.
Can drinking alcohol make my neuropathy worse?
Because alcohol is naturally toxic to peripheral nerves, regular or excessive drinking can speed up nerve damage. If you have a genetic vulnerability, it is best to limit your alcohol intake to protect your remaining nerve function.
How often do I need to check my feet if I have nerve damage?
You should inspect your feet every single day. Because neuropathy reduces physical sensation, you might not feel a minor cut, blister, or sore. Catching these early prevents them from turning into serious infections.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given my specific subtype, which medications are strictly off-limits for me to take?
  2. 2.Does my form of neuropathy carry any risk of affecting my heart or my breathing over time?
  3. 3.How often should I have my strength and balance re-evaluated to update my physical therapy plan?
  4. 4.Are there any specific vitamins or supplements, like Vitamin B6, that I should avoid or limit?
  5. 5.If I develop new pain or a sudden drop in function, what is the best way to determine if it is the disease progressing or a different issue?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    Hearing loss in inherited peripheral neuropathies: Molecular diagnosis by NGS in a French series.

    Lerat J, Magdelaine C, Roux AF, et al.

    Molecular genetics & genomic medicine 2019; (7(9)):e839 doi:10.1002/mgg3.839.

    PMID: 31393079
  2. 2

    Understanding medication safety and Charcot-Marie-Tooth disease: a patient perspective.

    Socha Hernandez AV, Deeks LS, Shield AJ

    International journal of clinical pharmacy 2020; (42(6)):1507-1514 doi:10.1007/s11096-020-01123-z.

    PMID: 32804316
  3. 3

    On the path to evidence-based therapy in neuromuscular disorders.

    Younger DS

    Handbook of clinical neurology 2023; (195()):315-358 doi:10.1016/B978-0-323-98818-6.00007-8.

    PMID: 37562877
  4. 4

    New developments in Charcot-Marie-Tooth neuropathy and related diseases.

    Pareyson D, Saveri P, Pisciotta C

    Current opinion in neurology 2017; (30(5)):471-480 doi:10.1097/WCO.0000000000000474.

    PMID: 28678038
  5. 5

    Neurological update: hereditary neuropathies.

    Kramarz C, Rossor AM

    Journal of neurology 2022; (269(9)):5187-5191 doi:10.1007/s00415-022-11164-1.

    PMID: 35596796
  6. 6

    Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease.

    Adams D, Koike H, Slama M, Coelho T

    Nature reviews. Neurology 2019; (15(7)):387-404 doi:10.1038/s41582-019-0210-4.

    PMID: 31209302
  7. 7

    Toxic medications in Charcot-Marie-Tooth patients: A systematic review.

    Cavaletti G, Forsey K, Alberti P

    Journal of the peripheral nervous system : JPNS 2023; (28(3)):295-307 doi:10.1111/jns.12566.

    PMID: 37249082
  8. 8

    Heterozygosity for CMT Type 4 Predicts a Severe Vincristine-induced Polyneuropathy Phenotype: A Case Report and Review of Literature.

    Sy A, Cheng J, Cooper R, Mueller L

    Journal of pediatric hematology/oncology 2019; (41(1)):e41-e43 doi:10.1097/MPH.0000000000001230.

    PMID: 29877907
  9. 9

    A recurrent MORC2 mutation causes Charcot-Marie-Tooth disease type 2Z.

    Vujovic D, Cornblath DR, Scherer SS

    Journal of the peripheral nervous system : JPNS 2021; (26(2)):184-186 doi:10.1111/jns.12443.

    PMID: 33844363
  10. 10

    Correlates of functional ankle instability in children and adolescents with Charcot-Marie-Tooth disease.

    Rose KJ, Hiller CE, Mandarakas M, et al.

    Journal of foot and ankle research 2015; (8()):61 doi:10.1186/s13047-015-0118-1.

    PMID: 26543504
  11. 11

    The Role of Rehabilitation in the Management of Patients with Charcot-Marie-Tooth Disease: Report of Two Cases.

    Dimitrova EN, Božinovikj I, Ristovska S, et al.

    Open access Macedonian journal of medical sciences 2016; (4(3)):443-448 doi:10.3889/oamjms.2016.079.

    PMID: 27703571
  12. 12

    Frequency and circumstances of falls for people with Charcot-Marie-Tooth disease: A cross sectional survey.

    Ramdharry GM, Reilly-O'Donnell L, Grant R, Reilly MM

    Physiotherapy research international : the journal for researchers and clinicians in physical therapy 2018; (23(2)):e1702 doi:10.1002/pri.1702.

    PMID: 29282812
  13. 13

    Electrical storm in a patient with Charcot-Marie-Tooth disease treated with radiofrequency ablation and subsequent serious complication of implantable cardioverter defibrillator implantation: a case report.

    Vrtal J, Plášek J, Václavík J, et al.

    European heart journal. Case reports 2025; (9(1)):ytae673 doi:10.1093/ehjcr/ytae673.

    PMID: 39748939
  14. 14

    Patient-reported disease burden in the Accelerate Clinical Trials in Charcot-Marie-Tooth Disease Study.

    Rehbein T, Purks J, Dilek N, et al.

    Journal of the peripheral nervous system : JPNS 2024; (29(4)):487-493 doi:10.1111/jns.12662.

    PMID: 39390667
  15. 15

    The Charcot-Marie-Tooth Health Index: Evaluation of a Patient-Reported Outcome.

    Johnson NE, Heatwole C, Creigh P, et al.

    Annals of neurology 2018; (84(2)):225-233 doi:10.1002/ana.25282.

    PMID: 30014533
  16. 16

    Hereditary Neuromuscular Disorders in Reproductive Medicine.

    Luglio A, Maggi E, Riviello FN, et al.

    Genes 2024; (15(11)) doi:10.3390/genes15111409.

    PMID: 39596609

This page provides general long-term care guidelines for genetic neuropathies. It is for educational purposes only and does not replace professional medical advice. Always consult your neurologist before starting supplements or stopping medications.

Get notified when new evidence is published on Genetic peripheral neuropathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.